U.S. FDA approves Pfizer-BioNTech COVID-19 booster for 16- and 17-year-olds

2021-12-10 10:02:28

Asian Tech Press (Dec 10) -- The U.S. Food and Drug Administration (FDA) approved on Thursday a booster dose of the COVID-19 vaccine co-developed by Pfizer Inc. and German company BioNTech SE for 16- to 17-year-olds.

The FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, approving a single booster dose for administration to people aged 16 to 17 years at least six months after receiving a second dose of the Pfizer-BioNTech vaccine.

Last month, the FDA had approved a booster dose of Pfizer and Moderna's COVID-19 vaccine boosters to all individuals 18 years of age and older

FDA booster shot BioNTech Pfizer COVID

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Tencent Holdings repurchased 3.93 million shares for HK$1.5 billion on January 7
                            2025-01-07

                                    Ireland recorded a 12.8 billion euro fiscal surplus last year due to the "Apple tax" ruling
                            2025-01-07

                                    Ministry of Industry and Information Technology: Promoting technical verification of 10G optical network and artificial intelligence integration
                            2025-01-07

                                    Tencent's major shareholder Prosus reduced its stake in Tencent Holdings from 24.01% to 23.99% on January 6.
                            2025-01-07

                                    U.S. chip stocks rose before the market opened, with Nvidia up 0.6%
                            2025-01-07